Everest Medicines’ Partner Calliditas Therapeutics Reports Positive Topline Results for Nefecon in Phase 3 Clinical Trial for Primary IgA Nephropathy
Everest Medicines' partner, Calliditas Therapeutics AB, has reported positive topline results from the global Phase 3 clinical trial of NefIgArd. The trial investigated the effects of Nefecon versus p ...
Everest Medicines Announces South Korea Grants Fast-Track Review Designation to Nefecon for Primary IgA Nephropathy Treatment
Everest Medicines, a biopharmaceutical company developing and commercializing innovative pharmaceuticals and vaccines in Asia, has received Global Innovative product on Fast Track (GIFT) designation f ...